Must Read: AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution

Seeking Alpha's Must Reads AbbVie: Inexpensive, High-Yield Dividend Aristocrat With Strong Execution AbbVie (ABBV) is a major biopharma company that continues to generate compelling results on the back of ongoing Humira strength and growth of other businesses, such as its oncology franchise. 7.6% Yielding Enbridge Is The 'Growth King' Of Midstream The energy industry is at the beginning of a decades-long transition to a carbon-neutral world. This means even the most stable of oil and gas companies may find it challenging to deliver steady cash Searching For Opportunity In The Green Energy Sell-Off With the recent sell-off in green energy finally making some stocks in the sector look a bit less overbought, we are looking for buying opportunities. Renewable energy was one of the darlings of 20... Canadian Solar: Cheap Solar Energy Play Canadian Solar Inc. (CSIQ) is cheaply valued. Especially considering its growth potential. The company has a strong backlog in energy projects and plans significant production capacity expansion. It. How To Play The Reopening Trade In Real Estate It seems as though the economy is well on its way to recovering and businesses are opening back up. With market prices still depressed in many sectors, there are some big opportunities in owning th... Download Seeking Alpha for your Phone or Tablet Do you like the content of the Must Reads? How can we improve? Just reply to this email. Sent by Seeking Alpha, 52 Vanderbilt Avenue, 13th floor, New York, NY 10017 By default, clicking links in Seeking Alpha emails auto-logs you into the site. Be careful not to forward this email to anyone you don't want having access to your account. You can change your email security settings here (keep in mind that disabling email auto-login will likely require you to log into your account more frequently). Why are you receiving this? You subscribed to Must Reads at Seeking Alpha. Don't like this email? Unsubscribe here.

Share this

Share on FacebookPlus on Google+